Sanofi SA

As of June 30, 2026, Sanofi SA has 1.21B shares outstanding.

As of June 30, 2026, Sanofi SA maintains a current ratio of 0.99, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.89, indicating elevated leverage, while an interest coverage ratio of 10.74 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Sanofi SA posted a return on equity (ROE) of 5.69, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.79 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.12, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.82, useful for judging operating efficiency across full business cycles. The company generates approximately 575,015.68 in revenue per employee across its workforce of 78,516.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.79 indicates how many times Sanofi SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Sanofi SA recorded 1.11B in income tax expense. That works out to an effective tax rate of 22.14, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.01B, leaving 3.65B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 13, 2026, Sanofi SA's stock has declined approximately 21.32% over the past 52 weeks. The 50-day moving average sits at 81.74, while the 200-day moving average is 84.50.

Over the twelve months ended June 30, 2026, Sanofi SA generated 45.15B in revenue and converted that into 3.65B in net income, yielding earnings per share of 3.05. EBITDA reached 7.23B, while operating income came in at 9.29B.

As of June 30, 2026, Sanofi SA holds 5.86B in cash and equivalents against 21.76B in total debt, resulting in a net debt position of 14.14B. Total book value stands at 63.87B, with working capital of -376.55M providing operational flexibility.

Sanofi SA produced 10.93B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sanofi SA posted a gross margin of 72.77, reflecting its pricing power and cost economics. The operating margin of 20.58 and net profit margin of 8.09 provide insight into operational efficiency.

Sanofi SA's most recent stock split took place on May 24, 1999 with a 1:4 split ratio.